Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) FCF Margin: 2010-2025

Historic FCF Margin for Ani Pharmaceuticals (ANIP) over the last 16 years, with Sep 2025 value amounting to 16.66%.

  • Ani Pharmaceuticals' FCF Margin rose 1149.00% to 16.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.83%, marking a year-over-year increase of 501.00%. This contributed to the annual value of 7.78% for FY2024, which is 1484.00% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' FCF Margin is 16.66%, which was down 50.96% from 33.97% recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' FCF Margin peaked at 178.30% during Q1 2021, and registered a low of -32.40% during Q1 2022.
  • Its 3-year average for FCF Margin is 17.04%, with a median of 16.50% in 2025.
  • In the last 5 years, Ani Pharmaceuticals' FCF Margin spiked by 17,796bps in 2021 and then slumped by 21,070bps in 2022.
  • Ani Pharmaceuticals' FCF Margin (Quarterly) stood at -20.58% in 2021, then skyrocketed by 1,258bps to -8.00% in 2022, then surged by 4,025bps to 32.25% in 2023, then plummeted by 2,519bps to 7.07% in 2024, then soared by 1,149bps to 16.66% in 2025.
  • Its FCF Margin stands at 16.66% for Q3 2025, versus 33.97% for Q2 2025 and 16.50% for Q1 2025.